AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02773524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
Study NCT02828618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDS (Primary Debulkdung Surgery)
Description: PDS with maximum effort to achieve the goal of complete gross resection
Study NCT02828618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 cycles of standard chemotherapy
Description: 6 cycles of standard chemotherapy after Primary Debuling Surgery
Study NCT02828618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Timing of surgery after 3 cycles of standard NACT, IDS
Description: Timing of surgery after 3 cycles of standard NACT
Study NCT02828618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IDS
Description: IDS with maximum effort to achieve the goal of complete gross resection after NACT
Study NCT02828618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 cycles of standard chemotherapy
Description: 3 more cycles (for a total of 6) of standard chemotherapy after IDS
Study NCT01571570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg capsule
Description: single oral dose of 150 mg TMC435 150 mg capsule
Study NCT01571570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg oral suspension (20 mg/mL)
Description: single oral dose of 150 mg TMC435 oral suspension
Study NCT01571570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg oral solution (10 mg/mL)
Description: single oral dose of 150 mg TMC435 oral solution
Study NCT01571570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg capsule concept K
Description: single oral dose of 150 mg TMC435 capsule concept K
Study NCT01571570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg capsule concept L
Description: single oral dose of 150 mg TMC435 capsule concept L
Study NCT02885636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: : Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose
Study NCT02885636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Saline inhaled through a nebulizer as a single dose
Study NCT03434587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Syndactyly
Description: Syndactyly
Study NCT03434587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction and inmobilization
Description: Closed reduction and inmobilization with splint
Study NCT01255293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5000 centistoke silicone oil
Description: Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
Study NCT01830205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT04146116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal povidone-iodine
Description: povidone-iodine USP, 10% w/w antiseptic
Study NCT02923986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 (varying dose)
Description: BP1001 (varying dose)
Study NCT00665340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00665340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5m, 10 mg and 20 mg 1 h prior to sexual intercourse
Study NCT01150916 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BNP, SAAG, ascites total protein, echocardiography
Description: diagnostic tests
Study NCT02923986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 (fixed dose)
Description: BP1001 (fixed dose)
Study NCT02923986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib
Study NCT01525264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIM-CHI
Description: The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
Study NCT02172872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard combination chemotherapy
Description: 1. Cycle 1~   1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~2. Cycle 2~   1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~3. Cycle 3 (mini-ICE)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days~4. Cycle 4 (mini-ICE) (optional)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days
Study NCT02172872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: 1. Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days~2. Cycle 2~   1. if bone marrow (BM) blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~3. Cycle 3~   1. if BM blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~4. Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days~5. Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days~Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available.
Study NCT00448669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
Study NCT00448669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT01525264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Wife Control Group
Description: Intervention group of couples who received education about importance of Healthy diet
Study NCT00252239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenecteplase
Description: This study will compare 3 different doses of tenecteplase to tPA.
Study NCT00252239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator, tPA
Description: To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
Study NCT01687478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Administered Orally
Study NCT01687478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Administered Orally
Study NCT01687478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine
Description: Administered Orally
Study NCT01687478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally
Study NCT01751932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM Monitoring
Description: All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
Study NCT02511821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Complete online surveys
Study NCT02511821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivofit watch
Description: Wear Vivofit watch
Study NCT02511821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02511821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03213730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-MOT Neurotracker
Description: A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks.
Study NCT03213730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Attention Intervention
Description: The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
Study NCT00654758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M200 (Volociximab), Carboplatin, Paclitaxel
Description: Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
Study NCT01898650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR scan
Study NCT00117325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: Aqueous Nasal Spray 100mcg
Study NCT04257045 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Participate in semi-structure, in-depth qualitative interviews
Study NCT04287985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose-Placebo
Description: Unit Dose Strength - 0.9%.
Study NCT01002222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS-2
Description: 15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
Study NCT01998776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 200ug four times daily
Study NCT01998776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Starch four times daily
Study NCT04257045 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT04257045 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT02802631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocin (minocycline) for Injection
Description: Intravenous formulation of minocycline, a derivative of tetracycline
Study NCT02802631 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Normal Saline
Study NCT03796039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Description: Standing for an additional 100 minutes per week; 20 minutes Monday-Friday
Study NCT03427593 — intervention group
Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: FACS analyses
Description: FACS analyses
Study NCT03427593 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FACS analyses
Description: FACS analyses
Study NCT03427593 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: FACS analyses
Description: FACS analyses
Study NCT03427593 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Target Sequencing by NGS ( Next-generation sequencing)
Description: Target Sequencing by NGS ( Next-generation sequencing)
Study NCT03427593 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Target Sequencing by NGS ( Next-generation sequencing)
Description: Target Sequencing by NGS ( Next-generation sequencing)
Study NCT03427593 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole Exome Sequencing
Description: Whole Exome Sequencing
Study NCT03427593 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Whole Exome Sequencing
Description: Whole Exome Sequencing
Study NCT04005469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
Study NCT02782234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contract management
Study NCT01378650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Administration of Cilostazol 100mg twice a day for 4 weeks
Study NCT01378650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo one tablet matching for cilostazol twice a day for 4 weeks.
Study NCT00742222 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Electronic Brachytherapy
Description: 34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
Study NCT00742222 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intracavitary accelerated partial breast irradiation
Description: 3.4 Gy BID x 5 days
Study NCT00723151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Milieu Communication Teaching
Description: Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
Study NCT00493610 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine(Mucomyst)
Study NCT01089569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
Study NCT03352999 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fast track access to vaECMO
Description: ROHCA must be witnessed with onset of bystander CPR and an immediate call to Emergency Dispatch. Furthermore, to minimize any loss of time, all qualified geographical locations are directly incorporated in the regulation software of the center for medical emergency control.~Patients suitable for vaECMO implantation were identified as early as possible by the Medical Dispatcher at the Emergency Call Dispatch Center.~Bystanders pursued CPR until Mobile Intensive Care Unit (MICU) arrival. OHCA was considered refractory after 10 min of CPR initiating the transport by MICU to the hospital such that the vaECMO intervention could be performed. The resuscitation was pursued during the transfer to hospital. An automated chest compression device was used in order to minimize interruption periods.~The intensivists and cardiac surgeons stood ready to implant the vaECMO surgically in the catheterization laboratory where a percutaneous coronary intervention was subsequently performed.
Study NCT00023933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody CC49-deltaCH2
Description: Given IV
Study NCT03377816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
Study NCT03377816 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Art Therapy
Description: In a group setting participants will engage in Mandala coloring
Study NCT01089569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: .1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
Study NCT02003976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medial Opening Wedge High Tibial Osteotomy (HTO)
Description: A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
Study NCT02003976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical Treatment Program
Description: A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
Study NCT02003976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Surgical Treatment Program
Description: A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
Study NCT02762708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Description: Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
Study NCT02762708 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Caloric Restriction
Description: Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
Study NCT02762708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery.
Study NCT02762708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery.
Study NCT01463163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
Study NCT01463163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
Study NCT00758069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: 100 mg once daily (QD), taken orally for 4 weeks
Study NCT00758069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablet, QD, taken orally for 4 weeks